Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
EXAS Stock Forecast 2026-2027
$103.27
Current Price
$19.71B
Market Cap
Buy 2
Hold 20
Sell 0
Wall St Analyst Ratings
Distance to EXAS Price Targets
+14.3%
To High Target of $118.00
+1.7%
To Median Target of $105.00
+1.7%
To Low Target of $105.00
EXAS Price Momentum
-0.2%
1 Week Change
+0.0%
1 Month Change
+139.9%
1 Year Change
+1.7%
Year-to-Date Change
-0.5%
From 52W High of $103.75
+166.1%
From 52W Low of $38.81
📊 TOP ANALYST CALLS
Did EXAS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Exact Sciences is one of their latest high-conviction picks.
Latest EXAS Stock Price Targets & Analyst Predictions
Based on our analysis of 35 Wall Street analysts, EXAS has a neutral consensus with a median price target of $105.00 (ranging from $105.00 to $118.00). The overall analyst rating is Buy (6.3/10). Currently trading at $103.27, the median forecast implies a 1.7% upside. This outlook is supported by 2 Buy, 20 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Anthony Petrone at Mizuho, suggesting a 1.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EXAS Analyst Ratings
2
Buy
20
Hold
0
Sell
EXAS Price Target Range
Low
$105.00
Average
$105.00
High
$118.00
Current: $103.27
Latest EXAS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EXAS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 20, 2026 | Mizuho | Anthony Petrone | Neutral | Downgrade | $105.00 |
| Jan 5, 2026 | Evercore ISI Group | Vijay Kumar | In-Line | Downgrade | $105.00 |
| Nov 28, 2025 | Stifel | Daniel Arias | Hold | Downgrade | $105.00 |
| Nov 25, 2025 | Canaccord Genuity | Kyle Mikson | Hold | Downgrade | $105.00 |
| Nov 24, 2025 | Benchmark | Bruce D. Jackson | Hold | Downgrade | $N/A |
| Nov 24, 2025 | Jefferies | Brandon Couillard | Hold | Downgrade | $105.00 |
| Nov 21, 2025 | Guggenheim | Subbu Nambi | Neutral | Downgrade | $N/A |
| Nov 21, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Downgrade | $105.00 |
| Nov 21, 2025 | William Blair | Andrew Brackmann | Market Perform | Downgrade | $N/A |
| Nov 21, 2025 | Barclays | Luke Sergott | Equal-Weight | Downgrade | $105.00 |
| Nov 20, 2025 | BTIG | Mark Massaro | Neutral | Downgrade | $N/A |
| Nov 11, 2025 | Piper Sandler | David Westenberg | Overweight | Maintains | $80.00 |
| Nov 5, 2025 | Wells Fargo | Brandon Couillard | Overweight | Maintains | $85.00 |
| Nov 4, 2025 | Guggenheim | Subbu Nambi | Buy | Maintains | $75.00 |
| Nov 4, 2025 | BTIG | Mark Massaro | Buy | Maintains | $85.00 |
| Nov 4, 2025 | Baird | Catherine Schulte | Outperform | Maintains | $88.00 |
| Nov 4, 2025 | Benchmark | Bruce D. Jackson | Buy | Maintains | $75.00 |
| Nov 4, 2025 | TD Cowen | Dan Brennan | Buy | Maintains | $90.00 |
| Nov 4, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $77.00 |
| Nov 4, 2025 | Stifel | Daniel Arias | Buy | Maintains | $80.00 |
Exact Sciences Corp (EXAS) Competitors
The following stocks are similar to Exact Sciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
EXAS
Exact Sciences
mkt cap
19.76B
Exact Sciences Corp (EXAS) Financial Data
Exact Sciences Corp has a market capitalization of $19.71B with a P/E ratio of -93.9x. The company generates $3.25B in trailing twelve-month revenue with a -6.4% profit margin.
Revenue growth is +23.1% quarter-over-quarter, while maintaining an operating margin of -9.3% and return on equity of -8.7%.
Valuation Metrics
Market Cap
$19.71B
Enterprise Value
$21.31B
P/E Ratio
-93.9x
PEG Ratio
55.0x
Price/Sales
6.1x
Growth & Margins
Revenue Growth (YoY)
+23.1%
Gross Margin
+70.1%
Operating Margin
-9.3%
Net Margin
-6.4%
EPS Growth
+23.1%
Financial Health
Cash/Price Ratio
+4.9%
Current Ratio
2.4x
Debt/Equity
105.6x
ROE
-8.7%
ROA
-1.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Exact Sciences Corp (EXAS) Business Model
About Exact Sciences Corp
What They Do
Molecular diagnostics for cancer screening and detection.
Business Model
The company generates revenue primarily through its flagship product, Cologuard, which offers non-invasive colorectal cancer screening. Additionally, Exact Sciences earns income from its suite of genomic assays that provide risk assessment and treatment benefits for breast and colon cancer patients, as well as other diagnostic tests that cater to the precision oncology market.
Additional Information
Founded in 1995 and headquartered in Madison, Wisconsin, Exact Sciences Corp operates both domestically and internationally. The company is committed to improving cancer diagnostics and treatment options, supporting healthcare providers and patients in prevention and personalized care initiatives.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
7,100
CEO
Mr. Kevin T. Conroy J.D.
Country
United States
IPO Year
2001
Website
www.exactsciences.comExact Sciences Corp (EXAS) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Exact Sciences (EXAS) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Mar 11, 2026
By Zacks Equity Research
Tale of the Tape
CSLLY or EXAS: Which Is the Better Value Stock Right Now?
CSLLY vs. EXAS: Which Stock Is the Better Value Option?
Mar 04, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Zacks Style Scores can help investors select strong, market-beating stocks for their portfolios.
Why It Matters
The Zacks Style Scores can help investors identify high-potential stocks, potentially leading to better portfolio performance and returns.
Source: Zacks Investment Research
Market Sentiment:
Positive
Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year
9 days ago
Quick Summary
Exact Sciences Corp. (NASDAQ: EXAS) has received the Gallup Exceptional Workplace Award for 2026, marking its third consecutive year of recognition for employee engagement and workplace culture.
Why It Matters
Exact Sciences' third consecutive Gallup Exceptional Workplace Award signals strong employee engagement and corporate culture, potentially leading to better performance and profitability, attracting investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Investors are comparing CSL Limited Sponsored ADR (CSLLY) and Exact Sciences (EXAS) for potential value opportunities in the Medical - Biomedical and Genetics sector.
Why It Matters
The comparison highlights potential investment opportunities in the biomedical sector, indicating which stock may offer better value and growth prospects, influencing investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Amalgam Rx, Inc. announced results from a colorectal cancer screening program led by Privia Health (NASDAQ: PRVA), showing increased screening rates through EHR integration and patient outreach.
Why It Matters
The announcement highlights successful collaboration in healthcare technology, potentially boosting stock values for involved companies and indicating growth in AI-driven healthcare solutions.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
EXAS reports Q4 revenue exceeded expectations, driven by growth in Screening and Precision Oncology, with expanding margins. Shares increased amid ongoing Abbott merger plans.
Why It Matters
EXAS's revenue beat signals strong growth potential, particularly in Screening and Precision Oncology, which may boost investor confidence and share prices amid merger developments.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Zacks Style Scores can help investors identify strong, market-beating stocks for their portfolios.
Why It Matters
The Zacks Style Scores provide a systematic approach to identify high-performing stocks, potentially enhancing portfolio returns and guiding investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About EXAS Stock
What is Exact Sciences Corp's (EXAS) stock forecast for 2026?
Based on our analysis of 35 Wall Street analysts, Exact Sciences Corp (EXAS) has a median price target of $105.00. The highest price target is $118.00 and the lowest is $105.00.
Is EXAS stock a good investment in 2026?
According to current analyst ratings, EXAS has 2 Buy ratings, 20 Hold ratings, and 0 Sell ratings. The stock is currently trading at $103.27. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EXAS stock?
Wall Street analysts predict EXAS stock could reach $105.00 in the next 12 months. This represents a 1.7% increase from the current price of $103.27. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Exact Sciences Corp's business model?
The company generates revenue primarily through its flagship product, Cologuard, which offers non-invasive colorectal cancer screening. Additionally, Exact Sciences earns income from its suite of genomic assays that provide risk assessment and treatment benefits for breast and colon cancer patients, as well as other diagnostic tests that cater to the precision oncology market.
What is the highest forecasted price for EXAS Exact Sciences Corp?
The highest price target for EXAS is $118.00 from at , which represents a 14.3% increase from the current price of $103.27.
What is the lowest forecasted price for EXAS Exact Sciences Corp?
The lowest price target for EXAS is $105.00 from Anthony Petrone at Mizuho, which represents a 1.7% increase from the current price of $103.27.
What is the overall EXAS consensus from analysts for Exact Sciences Corp?
The overall analyst consensus for EXAS is neutral. Out of 35 Wall Street analysts, 2 rate it as Buy, 20 as Hold, and 0 as Sell, with a median price target of $105.00.
How accurate are EXAS stock price projections?
Stock price projections, including those for Exact Sciences Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 13, 2026 10:03 AM UTC